Nivolumab versus everolimus in advanced renal-cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Carcinoma, Renal Cell
  • Kidney Neoplasms
  • Sirolimus

abstract

  • Among patients with previously treated advanced renal-cell carcinoma, overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus. (Funded by Bristol-Myers Squibb; CheckMate 025 ClinicalTrials.gov number, NCT01668784.).

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1510665

PubMed ID

  • 26406148

Additional Document Info

start page

  • 1803

end page

  • 13

volume

  • 373

number

  • 19